Cancer Network is running a series I unofficially like to call “Everything you ever wanted to know about proteasome inhibitors but were afraid to ask.”
Maybe it should be “Too much information about proteasome inhibitors,” because some of this gets a bit heavy.
Here is a headline link to the first of two articles/studies on the subject:
By Michael Wang, MD | November 7, 2011Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, Texas
Current Advances in Novel Proteasome Inhibitor–Based Approaches to the Treatment of Relapsed/Refractory Multiple Myeloma
By Sagar Lonial, MD, Winship Cancer Institute and Lawrence H. Boise, PhD, Emory University Shool of Medicine, Atlanta, Georgia – November 7, 2011